|
EP1313734B1
(en)
|
2000-09-01 |
2009-11-11 |
Novartis Vaccines and Diagnostics, Inc. |
Aza heterocyclic derivatives and their therapeutic use
|
|
US20030028018A1
(en)
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
|
CZ304344B6
(cs)
*
|
2000-09-11 |
2014-03-19 |
Novartis Vaccines & Diagnostics, Inc. |
Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
|
|
US7642278B2
(en)
*
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
|
US7064215B2
(en)
*
|
2001-07-03 |
2006-06-20 |
Chiron Corporation |
Indazole benzimidazole compounds
|
|
AU2002349477A1
(en)
*
|
2001-11-26 |
2003-06-10 |
Takeda Chemical Industries, Ltd. |
Bicyclic derivative, process for producing the same, and use
|
|
US6822097B1
(en)
*
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
|
CA2488635C
(en)
*
|
2002-06-12 |
2012-10-23 |
Abbott Laboratories |
Antagonists of melanin concentrating hormone receptor
|
|
DE10238002A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Merck Patent Gmbh |
Benzimidazolderivate
|
|
CA2496164C
(en)
|
2002-08-23 |
2010-11-09 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
|
CN100526312C
(zh)
*
|
2002-08-23 |
2009-08-12 |
诺华疫苗和诊断公司 |
苯并咪唑喹啉酮及其应用
|
|
EP1545529A4
(en)
|
2002-09-30 |
2010-03-03 |
Bristol Myers Squibb Co |
NEW TYROSINE KINASE HEMMER
|
|
AU2003290699B2
(en)
*
|
2002-11-13 |
2009-08-27 |
Novartis Vaccines And Diagnostics, Inc. |
Methods of treating cancer and related methods
|
|
CN100377709C
(zh)
*
|
2002-11-13 |
2008-04-02 |
希龙公司 |
受体酪氨酸激酶抑制剂的制药用途及相关检测方法
|
|
US7329678B2
(en)
*
|
2003-01-28 |
2008-02-12 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US7893096B2
(en)
|
2003-03-28 |
2011-02-22 |
Novartis Vaccines And Diagnostics, Inc. |
Use of small molecule compounds for immunopotentiation
|
|
US7627675B2
(en)
*
|
2003-05-01 |
2009-12-01 |
Cisco Technology, Inc. |
Methods and devices for regulating traffic on a network
|
|
AU2004259755A1
(en)
*
|
2003-07-22 |
2005-02-03 |
Janssen Pharmaceutica, N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
JP4836788B2
(ja)
|
2003-07-23 |
2011-12-14 |
エグゼリクシス， インコーポレイテッド |
未分化リンパ腫キナーゼ変調因子及びその使用法
|
|
CN101160308B
(zh)
*
|
2003-11-07 |
2011-05-25 |
诺华疫苗和诊断公司 |
具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
|
|
CN102225926A
(zh)
*
|
2003-11-07 |
2011-10-26 |
诺华疫苗和诊断公司 |
具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
|
|
US20050192314A1
(en)
*
|
2003-11-13 |
2005-09-01 |
Ambit Biosciences Corporation |
Urea derivatives as C-kit modulators
|
|
WO2005053692A1
(en)
*
|
2003-12-01 |
2005-06-16 |
The Scripps Research Institute |
Advanced quinolinone based protein kinase inhibitors
|
|
US7875624B2
(en)
*
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
US7521446B2
(en)
|
2005-01-13 |
2009-04-21 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
US7759342B2
(en)
|
2005-01-13 |
2010-07-20 |
Signal Pharmaceuticals, Llc |
Methods of treatment and prevention using haloaryl substituted aminopurines
|
|
US7723340B2
(en)
|
2005-01-13 |
2010-05-25 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
KR101387985B1
(ko)
*
|
2005-01-27 |
2014-04-25 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
전이 종양의 치료
|
|
NZ599345A
(en)
|
2005-02-18 |
2013-07-26 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic Escherichia Coli
|
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
AU2006214064B2
(en)
|
2005-02-18 |
2012-04-26 |
J. Craig Venter Institute, Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
CA2608171C
(en)
*
|
2005-05-13 |
2014-02-04 |
Novartis Ag |
Use of quinolinone compounds for treating drug resistant cancers
|
|
JP5545925B2
(ja)
*
|
2005-05-17 |
2014-07-09 |
ノバルティス アーゲー |
ヘテロ環化合物の合成方法
|
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
|
MX2007014782A
(es)
|
2005-05-23 |
2008-02-19 |
Novartis Ag |
Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
|
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
|
CA2615626A1
(en)
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Small animal model for hcv replication
|
|
BRPI0617252A2
(pt)
*
|
2005-10-14 |
2011-07-19 |
Hoffmann La Roche |
regime de administração para benzodiazepina 5-2-clorofenil)-1,2-diidro-7-flìor-8-metóxi-3-metil-pira zolo [3,4-b] [1,4]
|
|
EP1951298A1
(en)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
|
ES2420829T3
(es)
|
2005-11-04 |
2013-08-27 |
Novartis Vaccines And Diagnostics S.R.L. |
Vacunas adyuvantadas con antígeno de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
|
DE102005054904A1
(de)
*
|
2005-11-17 |
2007-05-24 |
Wacker Polymer Systems Gmbh & Co. Kg |
Verfahren zur Herstellung polyvinylalkoholstabilisierter Latices
|
|
RU2433826C2
(ru)
*
|
2005-11-29 |
2011-11-20 |
Новартис Аг |
Композиции хинолинонов
|
|
JP2009523410A
(ja)
|
2005-12-08 |
2009-06-25 |
ノバルティス アクチエンゲゼルシャフト |
遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
EP3753574A1
(en)
|
2006-01-27 |
2020-12-23 |
Seqirus UK Limited |
Influenza vaccines containing hemagglutinin and matrix proteins
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
TW200803855A
(en)
*
|
2006-02-24 |
2008-01-16 |
Kalypsys Inc |
Quinolones useful as inducible nitric oxide synthase inhibitors
|
|
TWI417095B
(zh)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
|
|
WO2007109810A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
EP2004226A1
(en)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Storage of influenza vaccines without refrigeration
|
|
US20100285062A1
(en)
|
2006-03-31 |
2010-11-11 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
RU2008145225A
(ru)
|
2006-04-19 |
2010-05-27 |
Новартис АГ (CH) |
Соединения индазола и способы ингибирования cd7
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
US8138205B2
(en)
|
2006-07-07 |
2012-03-20 |
Kalypsys, Inc. |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
|
|
EP2037924A2
(en)
|
2006-07-07 |
2009-03-25 |
Steven P. Govek |
Bicyclic heteroaryl inhibitors of pde4
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
WO2008020330A2
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
|
ES2536401T3
(es)
|
2006-09-11 |
2015-05-25 |
Novartis Ag |
Fabricación de vacunas contra virus de la gripe sin usar huevos
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
JP5528807B2
(ja)
|
2006-10-12 |
2014-06-25 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
SG177141A1
(en)
|
2006-12-06 |
2012-01-30 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
|
EP2137184B1
(en)
*
|
2007-04-03 |
2013-05-08 |
Array Biopharma, Inc. |
Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
|
|
MX2009012117A
(es)
*
|
2007-05-09 |
2009-11-23 |
Pfizer |
Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos.
|
|
EA201070066A1
(ru)
|
2007-06-27 |
2010-06-30 |
Новартис Аг |
Вакцины против гриппа с низким содержанием добавок
|
|
GB0713880D0
(en)
*
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
US8252937B2
(en)
|
2007-09-14 |
2012-08-28 |
Janssen Pharmaceuticals, Inc. |
1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
|
|
PL2203439T3
(pl)
|
2007-09-14 |
2011-06-30 |
Addex Pharmaceuticals Sa |
1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
EP2240475B1
(en)
|
2007-12-20 |
2013-09-25 |
Novartis AG |
Thiazole derivatives used as pi 3 kinase inhibitors
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
WO2009115917A2
(en)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Improvements in preparation of influenza virus vaccine antigens
|
|
PE20091628A1
(es)
*
|
2008-03-19 |
2009-11-19 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
|
|
JP5547194B2
(ja)
|
2008-09-02 |
2014-07-09 |
ジャンセン ファーマシューティカルズ， インコーポレイテッド． |
代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
|
|
WO2010060589A1
(en)
|
2008-11-28 |
2010-06-03 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
|
CA2754618A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Ag |
Chlamydia antigens
|
|
MX2011010735A
(es)
|
2009-04-14 |
2012-01-25 |
Novartis Ag |
Composiciones para inmunizacion contra staphylococcus aureus.
|
|
FR2949344A1
(fr)
|
2009-04-27 |
2011-03-04 |
Novartis Ag |
Vaccins de protection contre la grippe
|
|
TWI410418B
(zh)
|
2009-04-29 |
2013-10-01 |
Ind Tech Res Inst |
氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
|
|
AR078411A1
(es)
|
2009-05-07 |
2011-11-09 |
Lilly Co Eli |
Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
|
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
MY153912A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
CN102439008B
(zh)
|
2009-05-12 |
2015-04-29 |
杨森制药有限公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
|
EP4218799A1
(en)
|
2009-07-15 |
2023-08-02 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
|
PL2464658T3
(pl)
|
2009-07-16 |
2015-03-31 |
Novartis Ag |
Immunogeny z Escherichia coli o zniesionej toksyczności
|
|
WO2011033588A1
(ja)
*
|
2009-09-18 |
2011-03-24 |
株式会社アドバンテスト |
試験装置および試験方法
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
US20120258940A1
(en)
|
2009-12-18 |
2012-10-11 |
Giordano Caponigro |
Method for treating haematological cancers
|
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
|
|
ES2707625T3
(es)
|
2010-04-16 |
2019-04-04 |
Novartis Ag |
Compuesto orgánico para su utilización en el tratamiento del cáncer de hígado
|
|
NZ602807A
(en)
|
2010-04-16 |
2014-02-28 |
Novartis Ag |
4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
|
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
UY33472A
(es)
|
2010-06-30 |
2012-01-31 |
Novartis Ag |
?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
ES2530345T3
(es)
|
2010-09-02 |
2015-03-02 |
Merck Patent Gmbh |
Derivados de pirazolopiridinona como antagonistas del receptor del LPA
|
|
JO3062B1
(ar)
|
2010-10-05 |
2017-03-15 |
Lilly Co Eli |
R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
|
|
EP2661435B1
(en)
|
2010-11-08 |
2015-08-19 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
|
CN103261195B
(zh)
|
2010-11-08 |
2015-09-02 |
杨森制药公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
|
|
PL2649069T3
(pl)
|
2010-11-08 |
2016-01-29 |
Janssen Pharmaceuticals Inc |
Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
|
|
AU2012211278B2
(en)
|
2011-01-26 |
2016-11-10 |
Glaxosmithkline Biologicals Sa |
RSV immunization regimen
|
|
JP5963777B2
(ja)
|
2011-01-31 |
2016-08-03 |
ノバルティス アーゲー |
新規ヘテロ環誘導体
|
|
WO2012125812A1
(en)
|
2011-03-17 |
2012-09-20 |
Novartis Ag |
Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
|
|
DK2707385T3
(da)
|
2011-05-13 |
2017-11-20 |
Glaxosmithkline Biologicals Sa |
RSV-F-præfusionsantigener
|
|
BR112013029246A2
(pt)
|
2011-05-19 |
2017-02-14 |
Novartis Ag |
4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
JP2014526506A
(ja)
|
2011-09-15 |
2014-10-06 |
ノバルティス アーゲー |
中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用
|
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
|
CN104039790B
(zh)
|
2011-10-28 |
2016-04-13 |
诺华股份有限公司 |
嘌呤衍生物及它们在治疗疾病中的应用
|
|
EP2776069A1
(en)
|
2011-11-07 |
2014-09-17 |
Novartis AG |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
|
JP2015505562A
(ja)
|
2012-01-31 |
2015-02-23 |
ノバルティス アーゲー |
Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
|
|
KR20150009540A
(ko)
|
2012-05-16 |
2015-01-26 |
노파르티스 아게 |
Pi-3 키나제 억제제에 대한 투여 요법
|
|
US20150202203A1
(en)
|
2012-07-11 |
2015-07-23 |
Novartis Ag |
Method of Treating Gastrointestinal Stromal Tumors
|
|
WO2014053521A2
(en)
|
2012-10-02 |
2014-04-10 |
Novartis Ag |
Nonlinear saccharide conjugates
|
|
WO2014058785A1
(en)
|
2012-10-10 |
2014-04-17 |
Novartis Ag |
Combination therapy
|
|
CN103804353A
(zh)
*
|
2012-11-01 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
|
RS56886B1
(sr)
|
2012-11-30 |
2018-04-30 |
Glaxosmithkline Biologicals Sa |
Antigeni pseudomonasa i kombinacije antigena
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
JP6669499B2
(ja)
|
2013-02-15 |
2020-03-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物
|
|
JP2016510000A
(ja)
|
2013-02-20 |
2016-04-04 |
カラ ファーマシューティカルズ インコーポレイテッド |
治療用化合物およびその使用
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
EP3003377A1
(en)
|
2013-05-31 |
2016-04-13 |
Novartis AG |
Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
|
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
|
CN105636945B
(zh)
|
2013-10-14 |
2017-11-17 |
卫材R&D管理有限公司 |
选择性取代的喹啉化合物
|
|
JP6223563B2
(ja)
|
2013-10-14 |
2017-11-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
選択的に置換されたキノリン化合物
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
NZ719185A
(en)
|
2013-11-01 |
2017-11-24 |
Kala Pharmaceuticals Inc |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
SI3076969T1
(sl)
|
2013-12-06 |
2021-12-31 |
Novartis Ag |
Režim omderjanja izooblike alfa selektivnega zaviralca fosfatidilino- zitol 3-kinaze
|
|
HUE053734T2
(hu)
|
2014-01-21 |
2021-07-28 |
Janssen Pharmaceutica Nv |
2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
|
|
KR20220049612A
(ko)
|
2014-01-21 |
2022-04-21 |
얀센 파마슈티카 엔.브이. |
대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
CN107075480A
(zh)
|
2014-07-09 |
2017-08-18 |
Tc生物制药有限公司 |
γδT细胞及其用途
|
|
US20170304313A1
(en)
|
2014-10-06 |
2017-10-26 |
Novartis Ag |
Therapeutic Combination For The Treatment Of Cancer
|
|
KR101693781B1
(ko)
*
|
2014-10-06 |
2017-01-09 |
한양대학교 에리카산학협력단 |
다이플루오로알킬기가 도입된 방향족 화합물의 제조 방법
|
|
CN104774221B
(zh)
*
|
2015-03-19 |
2017-02-08 |
广西师范大学 |
喹啉酮衍生物的金属配合物及其合成方法及应用
|
|
CN104725431B
(zh)
*
|
2015-03-19 |
2017-05-17 |
广西师范大学 |
喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用
|
|
CN104817535A
(zh)
*
|
2015-03-19 |
2015-08-05 |
广西师范大学 |
一种喹啉酮衍生物及其合成方法及应用
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
EP3333157B1
(en)
|
2015-08-07 |
2020-12-23 |
Harbin Zhenbao Pharmaceutical Co., Ltd. |
Vinyl compounds as fgfr and vegfr inhibitors
|
|
AR105911A1
(es)
|
2015-09-03 |
2017-11-22 |
Forma Therapeutics Inc |
Inhibidores de hdac8 bicíclicos fusionados [6,6]
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
US20180280370A1
(en)
|
2015-11-02 |
2018-10-04 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
|
EP3231434A1
(en)
|
2016-04-14 |
2017-10-18 |
Fundacio Centre de Regulacio Genomica |
Method of treatment of parkinsonism
|
|
AU2017324713B2
(en)
|
2016-09-08 |
2020-08-13 |
KALA BIO, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
KR20190051010A
(ko)
|
2016-09-08 |
2019-05-14 |
칼라 파마슈티컬스, 인크. |
치료 화합물의 결정형 및 그의 용도
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CN107935858B
(zh)
*
|
2016-10-12 |
2020-09-08 |
利尔化学股份有限公司 |
5-氟-2-硝基苯酚的制备方法
|
|
EP3645526B1
(en)
|
2017-06-27 |
2024-09-04 |
Janssen Pharmaceutica NV |
New quinolinone compounds
|
|
EP3713941B1
(en)
|
2017-11-24 |
2022-06-22 |
Janssen Pharmaceutica NV |
Pyrazolopyridinone compounds
|
|
KR102723359B1
(ko)
|
2017-11-24 |
2024-10-28 |
얀센 파마슈티카 엔브이 |
피라졸로피리디논 화합물
|
|
PT3722282T
(pt)
|
2017-12-07 |
2024-10-04 |
Harbin Zhenbao Pharmaceutical Co Ltd |
Forma de sal e forma cristalina que servem como compostos inibidores de fgfr e vegfr, e método de preparação para esse fim
|
|
CN109553534A
(zh)
*
|
2018-11-27 |
2019-04-02 |
常州大学 |
一种2-硝基-4-甲氧基苯甲酸的制备方法
|
|
MX2021007853A
(es)
|
2018-12-26 |
2021-08-11 |
Janssen Pharmaceutica Nv |
Compuestos de tienopiridinona.
|
|
US10835531B1
(en)
|
2019-06-18 |
2020-11-17 |
Oncology Venture ApS |
Methods for predicting drug responsiveness in cancer patients
|
|
GB201909191D0
(en)
*
|
2019-06-26 |
2019-08-07 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
CA3237696A1
(en)
|
2021-11-08 |
2023-05-11 |
Progentos Therapeutics, Inc. |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
WO2025085233A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Ensem Therapeutics, Inc. |
Novel derivatives of quinolinones, and compositions and methods thereof
|